Figure 1From: Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial Study design. (A) Open-label safety/PK component (4 weeks). (B) Double-blinded proof-of-concept component (12 weeks). *Patients without any disease activity requirements. BID, twice daily; MTX, methotrexate; PK, pharmacokinetics.Back to article page